Congratulations!
You’re One Step Away From Receiving the #1 AI Stock Under $10...
Act Fast! This Ultra-Cheap Stock Is Set to Blast Off
Welcome to The Oxford Communiqué.
You’re about to discover an AI stock that’s less than $10 now... but could trade for more than $100 in the next three years.
It reminds me of several of the biggest hits we’ve seen in the stock market.
Like when I gave a presentation on Tandem Diabetes Care in March 2018 when it was less than $4.
One year later, it was $74... a 1,700% gain.
Or better yet, Intuitive Surgical, which we first wrote about in 2004 at a split-adjusted price of $2.77.
The company’s surgical robots revolutionized medical care in America.
And today, for investors who decided to hang on for the last 20 years... the company trades more than 100 times higher... at more than $300 per share.
Why does this new AI company have that kind of potential?
Because this company is the future of AI and low-cost, ultra-fast drug discovery.
This technology has the potential to discover effective treatments up to 1,000 times faster than traditional methods.
It can dream up drugs “no one has ever seen.”
And it can do it at a fraction of the cost... doing with as few as 50 people what used to take 5,000.
Our company is pushing this tech forward with an exciting number of breakthroughs...
- The company is working on new treatments for solid tumors, including ovarian and breast cancer tumors.
- It published clinical results in Cancer Discovery that highlight the first AI-supported platform to guide the treatment of patients with advanced blood cancer.
- It completed the acquisition of Allcyte, integrating that company’s tissue platform into its own drug discovery operations.
- It launched its third collaboration – worth $70 million – with the Bill & Melinda Gates Foundation to create a portfolio of up to five antiviral drugs.
- Sanofi recently agreed to pay the company up to $5.2 billion to develop 15 experimental oncology and immunology drugs.
- It signed a major $1.2 billion partnership with Bristol Myers Squibb, one of the biggest pharmaceutical companies in the world.
- The company has a partnership with Japan’s huge pharma company Sumitomo Dainippon Pharma. Together they brought an AI-designed drug to clinical trials in one year... compared with the five it normally takes.
And yet this is just a small fraction of what the company has in the works.
I expect its sales to increase 111% by the end of the year.
And they could jump by billions of dollars in the years ahead.
Yet this stock trades for less than $10.
Rarely have I seen a stock with this much upside potential trading for so cheap.
But when I have, those stocks have turned into the best winners of my life.
I got in on Netflix, Amazon and Apple back when they were trading for just pennies on the dollar...
And I still hold all three today.
I’ve made enough on each to retire multiple times over.
And yet I consider this AI stock the greatest find of my career.
That’s why I want to send you my new report right away.
As you probably know, biotech stocks like this get huge boosts from major catalysts.
For example, I recommended ImmunoGen on May 2 this year, and it received excellent Phase 3 data on an ovarian cancer drug the next day.
The stock jumped 144%, making it the biggest winner in the entire market.
This new AI company is set to make headline news over and over going forward.
So you must be on board before the big moment.
Get All of My Promised Free Reports
Right Now
The first item I’ll send you is...
PLUS, You Get These Extra New-Member Bonuses!
- No. 3: A Free Copy of My Book Beyond Wealth: The Road Map to a Rich Life (Value: $21)
- No. 4: Free HD Video: A Free Set of The Millionaire-Maker Private Sessions (Value: $199)
- No. 5: “Ten-Baggers of Tomorrow: The Official Portfolio Guide” (Value: $139)
- No. 6: “The ‘All-Star Portfolio’ Strategy” (Value: $99)
- No. 7: Free Subscriptions to Our E-Letters, Liberty Through Wealth and Wealthy Retirement.
Total Value: $846!
You Get It All FREE Just for Becoming a New Subscriber to The Oxford Communiqué
You’ll get each of these bonuses free of charge just for subscribing to my flagship publication, The Oxford Communiqué.
The goals of our organization are pretty simple.
We help our Members...
- Maximize their income
- Minimize taxes
- Dominate the broad market returns every year
- Minimize market risks
- Live a financially free life without money worries or concerns.
In order to help you achieve these goals, you’ll receive one new issue of The Oxford Communiqué each month.
In it, I’ll give you my detailed analysis on a new investment opportunity. I’ll lay out why I believe the company is in prime position for a big move in the stock market.
You’ll get instructions on when to buy, what to pay and when to sell.
We also have an easy-to-track model portfolio so you can follow the gains each day... and see how much we’re beating the market by.
Beyond that, you’ll get our weekly Oxford Communiqué Portfolio Update... also for free. This will include market updates, notes on the latest earnings announcements and much more.
Consider, just one big win like Tandem Diabetes Care could have turned $4,000 into more than $74,000 in less than a year.
That’s why we’re convinced a subscription will be extremely valuable for you... especially when you consider the price.
The retail price of our flagship publication is just $249 per year. And our more than 170,000 Members will tell you it’s worth every penny.
But I’ve got unbelievable news for you today. A subscription can be yours for just a fraction of the normal price.
Right now, you can claim your Oxford Communiqué subscription for as little as $249 $49 (an 80% discount)... That’s less than $1 a week.
And next year, you’ll be auto-renewed at our lowest discounted rate, $79. Of course, there’s no obligation to do so. You can opt out of this feature at any time.
And remember, a subscription also comes with our full 365-day guarantee.
MY 365-DAY
100% MONEY-BACK GUARANTEE
You’ll have 12 months to use and review everything I’ve talked about today. You’ll see how the new AI stock performs.
You can track my Ten-Baggers of Tomorrow Portfolio. You can use any of the dozens of secrets in “The Multimillionaire’s Handbook.”
That’s how confident we are.
I have to say, I can’t imagine how I could make this offer any better.
This new AI stock I’ve found is without a doubt the best I’ve seen in my career – beating out Netflix, Apple, Intuitive Surgical and Celgene.
Buying it for less than $10 is a no-brainer.
But one last word of warning...
I believe the company’s big moment is coming up very soon.
AI is making big headlines every day.
Already this company has made the news with its landmark deal with Sanofi to develop 15 oncology and immunology drugs.
It brought the first AI-designed drug to human trials... speeding up the process to one year from the normal five.
And it has the potential for dozens of catalysts ahead that could create big moves in the stock.
If you wait, you may miss out completely.
Just fill out the secure order form below to get started.
And welcome to our financial club.
Sincerely,
Alexander Green
Editor, The Oxford Communiqué
Chief Investment Strategist, The Oxford Club
